Guselkumab in APEX study (PsA, n=1020, biologic-naïve): 🦴 Less joint damage: 0.55 vs 1.35 (placebo) 💪 More responders: 67–68% hit ACR20 on GUS 🛡 Safety: similar to placebo GUS - selective IL-23i - delivers joint protection and symptom relief LB0010 @RheumNow #EULAR2025